Human Synovial Lubricin Expresses Sialyl Lewis x
Determinant and Has L-selectin Ligand Activity*

Received for publication, March 16, 2012, and in revised form, July 20, 2012. Published, JBC Papers in Press, August 28, 2012, DOI 10.1074/jbc.M112.363119

Chunsheng Jin†1,2, Anna-Karin Hultgård Ekwall3, Johan Bylund4, Lena Björkman5, Ruby P. Estrella6, John M. Whitelock6, Thomas Eisel6, Maria Bokarewa7, and Niclas G. Karlsson8

From the 1Department of Medical Biochemistry, Institute of Biomedicine, and the 2Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 171 77 Stockholm, Sweden

Abstract: Lubricin is an abundant mucin-like glycoprotein in synovial fluid and a major component responsible for joint lubrication. In this study, it was shown that 0-linked core 2 oligosaccharides (Galβ1–3(GlcNAcβ1–6)GalNAcα1-Thr/Ser) on lubricin isolated from rheumatoid arthritis SF contained both sulfate and fucose residues, and SF lubricin was capable of binding to recombinant L-selectin in a glycosylation-dependent manner. Using resting human polymorphonuclear granulocytes (PMN) from peripheral blood, confocal microscopy showed that lubricin coated circulating PMN and that it partly co-localized with L-selectin expressed by these cells. In agreement with this, activation-induced shedding of L-selectin also mediated decreased lubricin binding to PMN. It was also found that PMN recruited to inflamed synovial area and fluid in rheumatoid arthritis patients kept a coat of lubricin. These observations suggest that lubricin is able to bind to PMN via an L-selectin-dependent and -independent manner and may play a role in PMN-mediated inflammation.

Lubricin is encoded by the PRG4 (proteoglycan 4) gene and synthesized by superficial zone chondrocytes and synoviocytes. Translated products of PRG4 have been referred to as superficial zone protein, megakaryocyte-stimulating factor precursor, camptodactyly-arthropathy-coxa vara-pericarditis protein, and hemangiopoietin (1–7). Alternative exon splicing of PRG4 transcripts and post-translational modifications lead to the differences in protein primary structure (4, 6). There are seven different isoforms of lubricin, six of which are identified in humans (1, 4, 6–9). They may have different biological functions. As a lubricating glycoprotein, the expression of lubricin has been found in synovial fluid (SF) (10), superficial layer of articular cartilage (11), tendons (12), and menisci (13). In addition, lubricin has been detected in blood and urine (7, 14). However, its extra-articular function is still poorly understood. In this study, we use “lubricin” when referring to the PRG4 gene products expressed in articular joints as well as in plasma.

Human lubricin is a secreted mucinous glycoprotein consisting of 1404 amino acids (1). Lubricin contains multiple protein domains, which probably contribute to its diverse biological properties, such as promoting growth in both pure and mixed megakaryocyte colonies, cytoprotection, matrix binding, dimerization, and inhibition of adhesion (1, 15, 16). The largest central mucin-like domain consists of 59 imperfectly repeated sequences of EPATTPK. This domain is flanked by a C-terminal hemopexin domain and two somatomedin B-like domains at the N terminus. In addition, a single putative glycosaminoglycan attachment site (D259EAGSG262) and heparin binding site (K134RSPKPPNKTKKV149) have been reported within the human lubricin primary sequence (1, 4, 11, 17).

Lubricin is responsible for the boundary lubrication of articular cartilage (18, 19). The O-glycans of lubricin have been assigned this function because removal of the ultimate and penultimate sugars (NeuAc and Gal residues) resulted in a loss of boundary lubricating ability (6). Recent studies indicate that lubricin also plays an important role in controlling adhesion-
dependent synovial growth (20), preventing protein deposition onto cartilage from synovial fluid and inhibiting the adhesion of synovial cells to the cartilage surface (1, 3, 12). Loss-of-function mutations in the PRG4 gene causes the camptodactyly-arthropathy-coxa vara-pericarditis syndrome in humans, a syndrome of precocious joint failure associated with non-inflammatory synovial hyperplasia and subintimal fibrosis of the joint capsule (3). Lubricin is found heterogeneously expressed in the synovium of rheumatoid arthritis (RA) and osteoarthritis (OA), implying a role in the pathogenesis of these diseases (21, 22). RA patients varied with respect to lubricin expression, where the patients with low levels of lubricin had more aggressive joint disease (22). A relationship between the pathogenesis of OA and down-regulation of lubricin has been suggested in several animal models (23–26). Furthermore, treatment of rat joints with injections of recombinant lubricin has indicated its protective effects on chondrocytes, suggesting the benefits of lubricating molecules as a possible therapy for OA (1, 16).

One of the hallmarks of RA is the infiltration of inflammatory cells, such as T cells, B cells, and macrophages, in the synovial tissue (27). The recruitment of leukocytes toward inflammatory foci is preceded by a highly coordinated sequence of interactions between leukocytes and endothelial cells, a process termed the adhesion cascade (28, 29). Polymorphonuclear granulocytes (PMN) or neutrophils are one of the first immune cells to be recruited at inflammatory foci. PMN, like other leukocytes, use L-selectin to roll along the endothelium in the initial phase of the adhesion cascade. In RA, PMN are rarely found in the synovial tissue. Instead, they accumulate in the synovial cavity (30). In particular, PMN have been reported at the pannus/cartilage border, where the joint destruction takes place, suggesting that these cells play an important role in the RA pathogenesis (31–33).

In our previous study, the O-glycans of lubricin were investigated (34). Approximately 30–35% of the total molecular mass of lubricin counts for O-glycosylation. Among them, core 1 O-linked oligosaccharides (Galβ1–3GalNAcα1–) and sialylated core 1 (Neu2–3Galβ1–3GalNAcα1– and Neu2–3Galβ1–3(NeuAca2–6)GalNAcα1–) were the predominant structures on lubricin. In addition, core 2 structures, such as NeuAca2–3Galβ1–3(NeuAca2–3Galβ1–3/4GlcNAcβ1–6)-GalNAcα1–, were also found in a low amount together with a small proportion of sulfated core 2 oligosaccharides. The presence of sulfated glycans indicates a potential L-selectin binding ability, especially if the sulfate is linked to the 6-position of GlcNAc on either extended core 1- or core 2-branched O-glycans (34). The optimal recognition by the C-type lectin domain of L-selectin requires sialylation, fucosylation, and sulfation (e.g. 6-sulfosialyl Lewis x (6-sulfosialyl Le^x), NeuAca2–3Galβ1–4(Fucα1–3)(6S)GlcNAcβ1–) of N- or O-linked glycans (35–38).

In this study, the linkage position of sulfation and potential fucosylation of lubricin were addressed. The ability of L-selectin and human PMN from peripheral blood and SF to bind lubricin were also investigated in order to discover a potential role of lubricin in inflammation.

**EXPERIMENTAL PROCEDURES**

**Human Synovial Tissue and Cells**—Synovial fluid samples from 10 RA patients (six rheumatoid factor (RF)-positive and four RF-negative) were collected during aseptic aspiration of knee joints at the Rheumatology Clinic, Sahlgrenska University Hospital (Gothenburg, Sweden). The RF-positive RA patients (age 58.8 ± 16.6; DAS28 3.7 ± 0.8) were treated with methotrexate (5), biologics (3), or corticosteroids (3); the RF-negative patients (age 67.5 ± 8.3; DAS28 3.7 ± 1.3) were treated with methotrexate (4). In addition, synovial tissue specimens were obtained from RA patients during joint replacement surgery at the Orthopedic Clinic, Sahlgrenska University Hospital. All patients gave informed consent, and the procedure was approved by the Ethics Committee of Gothenburg University. All RA patients fulfilled the American College of Rheumatology 1987 revised criteria for RA (39). One synovial fluid sample from a psoriatic arthritis patient was obtained from Royal Prince Alfred Hospital (Sydney, Australia) with the patient’s written consent.

**Enrichments of Native and Recombinant Lubricin**—Collected synovial fluid were clarified by centrifugation at 10,000 × g for 10 min and stored at −80 °C before use. The acidic proteins were purified as described previously (34). Lubricin-containing fractions were precipitated with 80% ethanol for 16 h at −20 °C. The precipitate was collected by centrifugation at 12,100 × g for 20 min and resuspended in phosphate-buffered saline (PBS) at pH 7.4 after air drying. Protein concentration was determined by BCA protein assay kit (Thermo Scientific, San Jose, CA) using bovine serum albumin (BSA) as a standard.

Stable CHO cells expressing full-length lubricin (accession number NM_005807) in pcDNA3.1 vector was generated by zeocin selection (40, 41). Serum-free medium, which contained recombinant lubricin, was enriched as native lubricin.

**Oligosaccharide Characterization**—Purified lubricin was reduced with 10 mM dithiothreitol (DTT) at 95 °C for 20 min and alkylated with 25 mM iodoacetamide for 1 h at room temperature in the dark before applying to a 3–8% Tris acetate gel (NuPAGE, Invitrogen). The gels were then transferred onto PVDF membrane (Immobilon P membranes, Millipore, Billerica, MA) using bovine serum albumin (BSA) as a standard.

Stable CHO cells expressing full-length lubricin (accession number NM_005807) in pcDNA3.1 vector was generated by a semiq method as described previously (42).

O-Linked oligosaccharides were released by reductive β-elimination from the Direct Blue 71-stained PVDF membrane corresponding to the area where lubricin was detected. In brief, membrane strips were incubated with 50 µl of 1.0 M NaBH₄ in 100 mM NaOH for 16 h at 50 °C. Reactions were quenched with 1 µl of glacial acetic acid, and samples were desalted and dried for capillary graphitized carbon LC-MS and LC-MS/MS in negative ion mode using an LTQ XL ion trap mass spectrometer (Thermo Scientific) (42). Oligosaccharides were identified from their MS/MS spectra using UniCarb-DB database (2011 version) (43) and validated manually. The annotated structures on lubricin are available on the UniCarb-DB database (available on the World Wide Web).

The Mann-Whitney U test was used for comparing two groups (RF-positive and RF-negative) for the degree of O-gly-
cosylation. A p value of 0.05 was considered to indicate statistical significance.

**Western Blotting, Inhibition ELISA, and Co-immunoprecipitation**—Samples were separated by electrophoresis either with 3–8% Tris acetate gel or with gradient SDS-agarose polyacrylamide composite gel (SDS-AgPAGE). Proteins blotted onto PVDF membranes were blocked with TBS-T buffer (Tris-buffered saline, pH 7.4, with 0.01% Tween 20) containing 1% BSA. After washing, membranes were incubated for 1 h at room temperature with mouse anti-lubricin antibody (mAb 13 and mAb 378, Pfizer Research, Cambridge, MA), mouse anti-sialyl Lewis x (CD15s or mAb CSLEX1, BD Biosciences), mouse anti-chondroitin sulfate (mAb CS56, Sigma-Aldrich), or recombinant human L-selectin/Fc chimera (human IgG1) chimera (R&D Systems, Minneapolis, MN) and subsequently incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated rabbit anti-mouse immunoglobulins (DakoCytomation, Glostrup, Denmark) and goat anti-human IgG (Fc-specific, Sigma-Aldrich), respectively. After washing, immunolabeled antibodies were visualized by SuperSignal West Femto maximum sensitivity substrate (Thermo Scientific).

To desialylate O-glycans, the reduced and alkylated samples were incubated with 5 milliunits of sialidase A (Prozyme Inc., Oxford, UK) at 37 °C for 16 h. The reaction was stopped by heating at 95 °C for 10 min in SDS-loading buffer. To characterize bound lubricin, human PMN were freshly isolated from heparinized peripheral blood from healthy volunteers (46). After dextran sedimentation at 1 × g and hypotonic lysis of the remaining erythrocytes, the PMN obtained by centrifugation in a Ficoll-Paque gradient were washed twice in Krebs-Ringer phosphate buffer. The cells were resuspended in Krebs-Ringer phosphate buffer and stored on ice as resting cells (1 × 10^7/ml).

For confocal immuno-fluorescence microscopy analysis, peripheral resting PMN were stained with an allophycocyanin-labeled anti-L-selectin antibody (clone DREG56, BioLegend, San Diego, CA) and rabbit anti-lubricin diluted in blocking buffer for 90 min on ice. After washing, cells were stained with a secondary fluorescein isothiocyanate isothiocyanate (FITC)-labeled swine anti-rabbit antibody (DakoCytomation) for 80 min on ice. Following a final wash, cells were air-dried on microscopic slides overnight protected from light.

**Flow Cytometric Analysis**—Resting PMN were incubated in Krebs-Ringer phosphate buffer alone or in the presence of 10 ng/ml recombinant TNF-α (Sigma-Aldrich) at 37 °C for 20 min. After washing, cells were incubated with different antibodies for 1 h on ice. For L-selectin detection, phycoerythrin-labeled anti-L-selectin antibody (CD62L, BD Biosciences) was used. After washing, bound lubricin was detected by the rabbit anti-lubricin antibody followed by a FITC-labeled swine anti-rabbit antibody (DakoCytomation). Samples were washed and
Lewis x and Sulfated O-Glycans Enable Synovial Lubricin to Bind L-selectin—The presence of sulfated O-glycans of synovial lubricin makes it a potential ligand for selectin binding (34). We were therefore interested to see if human SF lubricin can bind to L-selectin.

Synovial lubricin was purified from RA patients (n = 10). As shown in Fig. 1A, using lubricin-specific antibody (mAb 13), SF lubricin was detected as two bands both with an apparent molecular mass of >200 kDa when separated on SDS-agarose polyacrylamide composite gel under non-reducing conditions. Both bands were identified as lubricin by LC-MS after tryptic digestion (see below). The upper band is supposedly a dimer of SF lubricin, similar to that reported for bovine SF lubricin (47).

The separated SF lubricin was probed with recombinant human L-selectin/IgG chimera. As shown in Fig. 1A, RA SF lubricin from different patients was consistently shown to bind recombinant L-selectin. No binding was detected when SF lubricin was incubated with secondary antibody alone (goat anti-human IgG, Fc-specific; data not shown). Because interaction with L-selectin is sialylation-dependent, as expected, desialylation of lubricin by sialidase A diminished the interaction (Fig. 1A, Sialidase A). Sulfation is also required for high affinity L-selectin binding. When recombinant lubricin, expressed in CHO cells that do sialylate glycan but lack sulfation due to an inability to make core 2 structures, was incubated with L-selectin (Fig. 1A), no binding was detected, indicating that sulfation on O-glycan of lubricin was necessary for L-selectin binding. Although the presence of both sialylated and sulfated O-glycans on lubricin has been reported in our previous study (34), high affinity L-selectin ligand, 6-sulfo sLeX, was not detected on lubricin. Because our result indicated L-selectin binding despite the lack of this epitope, the level of L-selectin affinity was investigated further. Thus, an inhibition ELISA was performed (Fig. 1C). The results indicated that the binding of lubricin to L-selectin was inhibited by 6-sulfo LeX (90%), whereas bovine feutin (mainly sialylated glycans) and porcine gastric mucin (sulfated non-sialylated glycans) could only inhibit slightly (10%). These data indicate that lubricin is a moderate binder to L-selectin, between the level of a nonspecific sialylated and sulfated glycoprotein but not as good as previously reported high affinity ligand (48, 49).

L-selectin/IgG was also shown to capture lubricin in immunoprecipitation experiments. Silver staining of eluted sample revealed a band around 114 kDa representative of eluted L-selectin/IgG (Fig. 1B, Silver stain), and Western blot with mAb 13 revealed that lubricin was selectively enriched from SF (Fig. 1B, WB).

Presence of Lubricin in Serum and Binding to Peripheral PMN—In order to study the potential binding of lubricin to native L-selectin on leukocytes, we first investigated the presence of lubricin on freshly prepared PMN from peripheral blood. Using confocal microscopy, we found that lubricin
coated the surface of circulating PMN (Fig. 2, green). That lubricin associates with peripheral PMN in healthy subjects was further shown by immunoblotting of cell lysates (Fig. 2, B and C) and flow cytometry (Fig. 3) of isolated PMN samples.

The presence of lubricin in circulation was confirmed by Western blotting of serum from both healthy and RA patients (Fig. 2C). The result indicated that lubricin has a similar size and protein level in both RA and healthy sera. In addition, there was no apparent difference between synovial fluid and serum lubricin in size. As shown in Fig. 2D, the higher loading of lubricin in SF and serum manifests as increased polydispersity, whereas after purification and a lower amount of lubricin loaded, both SF lubricin and serum lubricin display similar apparent molecular mass. This indicated that lubricin from these two compartments displayed similar size. Preliminary data also indicated similar glycosylation on both proteins (data not shown).

We hypothesized that lubricin association with PMN is mediated by binding to L-selectin on the surface of these cells. Because L-selectin is cleaved off from activated PMN (44), we expected to find decreased lubricin levels on the surface-activated cells. We found that both the surface expression of L-selectin and the coating of lubricin were dramatically decreased after TNF activation, indicating that release of L-selectin and lubricin was mediated by the TNF signaling pathway (Fig. 3, A and B). Because lubricin is able to bind to L-selectin, it is possible that some lubricin binds to PMN via L-selectin, whereas other lubricin binds through unknown receptors. Confocal microscopy of resting peripheral PMN displayed partial colocalization (Fig. 2A, yellow) of these molecules, which strengthens the notion that lubricin binding to the surface of peripheral PMN is at least in part mediated via L-selectin. The addition of exogenous lubricin, purified from SF, to resting peripheral PMN resulted in a minor increase of lubricin binding (Fig. 3C).

These data demonstrate that lubricin is present not only in joints but also in serum and that circulating PMN are coated with lubricin under physiological conditions. Some, but not all,
L-selectin Ligand Activity of Lubricin

The presence of synovial lubricin in the synovial lining layer and on the surface of synovial PMN. Immunofluorescence analysis was carried out on synovial tissue specimens (A) and isolated synovial PMN (B) from RA patients. A, in the RA synovium, a large number of leukocytes (arrowheads) were present in germinal center-like structures in the sublining. Lubricin was only found within synoviocytes of the synovial lining layer (arrows). B, synovial PMN were isolated by centrifugation and washed with PBS. Lubricin was found on the surface of most PMN (arrows). C, representative flow cytometry plot of synovial cells stained with anti-lubricin antibody. The isolated cells were recognized as PMN (70%; 4), monocytes (5%; 3), lymphocytes (7%; 2), and nonspecific cells (1) by forward-side scatter. A majority of the PMN were coated with lubricin (green).

of this lubricin is removed from the cell surface concomitant with L-selectin shedding during cellular activation, strongly indicating that lubricin association with resting PMN is mediated by both L-selectin and by unknown receptors.

As mentioned above, in flares of RA, large numbers of neutrophils accumulate in the SF. Therefore, we next addressed whether lubricin could be associated with synovial PMN as well.

Synovial leukocytes were freshly isolated from SF of RA patients, and the PMN were identified on basis of their particular multilobulated nuclei. Most synovial PMN were coated with lubricin (Fig. 4, B (arrow) and C) in a similar manner as PMN from peripheral blood. Confocal immunofluorescence using RA synovial tissue specimens revealed positive cytoplasmic staining of lubricin in cells of the synovial lining (Fig. 4A). No continuous staining of the apical surface of the lining layer was found in these specimens. These findings suggest that adherence of lubricin to synovial PMN is specific and not just a casual coating of cells and tissues in the synovial cavity. In the synovium, only synovial fibroblasts were found to be lubricin-positive (Fig. 4A, arrows). Lubricin is absent on lymphocytes in synovium (Fig. 4A, arrowhead) and monocytes or lymphocytes in synovial fluid (Fig. 4B, arrowhead). Flow cytometric analysis of a synovial fluid sample isolated from an RA patient showed that all PMN were lubricin-positive, and the lubricin negative cells were also detected as monocytes or lymphocytes (Fig. 4C). Taken together, both peripheral and synovial PMN are covered by lubricin, some of which co-localize with L-selectin.

O-Linked Oligosaccharides of Synovial Lubricin Are Likely to Be Responsible for L-selectin Binding—Because binding to L-selectin requires 6-sulfo sLe^a and lubricin is able to bind to L-selectin, O-glycans of lubricin should contain 6-sulfo sLe^a, as expected. However, in our previous study, no fucosylated O-glycans or 6-sulfo sLe^a-containing O-glycans were found on synovial lubricin. Furthermore, the linkage and position of sulfate groups were not determined. The sulfate could link to C3 or C6 of Gal or C6 of GlcNAc residue resulting in 3'-sulfo, 6'-sulfo, and 6-sulfo O-glycan, respectively (34).

To characterize the position and linkage of sulfate groups as well as other modifications, such as fucosylation, O-linked oligosaccharide of synovial lubricin isolated from RA patients was released by reductive β-elimination as described previously (34); the entire oligosaccharide mixture was analyzed by porous graphitized carbon LC-electrospray ionization MS/MS. Core 1 type O-glycans were the predominant O-glycan structures (81.6%) on synovial lubricin from RA patients (n = 10). About 73% of core 1 and 50% of core 2 O-glycans were monosialylated. There were more monosialylated structures (68.5%) than disialylated structures (16.1%) (Fig. 6B). In comparison with RF-negative RA patients (n = 4), RF-positive patients (n = 6) have higher core 2 (21.3 ± 6.2% versus 14.2 ± 6.2%) and lower core 1 (78.7 ± 6.2% versus 85.8 ± 6.2%). However, the difference was not significant. RF-positive RA patients have significantly higher sulfated O-glycans than RF-negative ones (3.2 ± 1.2 versus 1.6 ± 1.6%, p = 0.038, Mann-Whitney test).

In the mass spectrum analysis, oligosaccharides corresponding to sialylated and sulfated core 2 structures were detected (Fig. 5). The biosynthetic precursor of the non-sulfated core 2 structure with the composition Hex2HexNAc2 ([M – H]^− ions of m/z 749) was identified as a single isomer (Fig. 5A) by LC/MS/MS. The presence of the 4A3 fragment ion (m/z 424) was consistent with an N-acetyllactosamine elongation on the C-6 of the GalNAcO. The 0.2A2, and 0.2A2H2O fragment ions (m/z 281 and 263) indicated Hex2HexNAc, contained in a type 2 (Galβ1–4GlcNAcβ1–6Galβ1–3GalNAca1 (50). Sulfated structures were also detected and sequenced after desialylation. To determine the position and linkage of the sulfated core 2 O-glycan, the [M – H]^− ions of m/z 829 were chosen for fragmentation. The presence of ions at m/z 282, 444, and 667 in MS/MS spectrum (Fig. 5B) indicated that the sulfate group was linked to GlcNAc and not to the Gal residue. The MS^3 spectrum showed fragmentation at m/z 97 (HSO_4^-) and 139 (0.4A_GlcNAc, OCHCH_3SO_4^-), which further confirmed the presence of sulfate (m/z 97) and sulfate residue linked to C-6 of GlcNAc but not to C-3 of GlcNAc (Fig. 5B, inset) (51). Therefore, ions at m/z 829 were assigned as 6-sulfo core 2 type O-glycans. Sialylated sulfated core 2 O-glycans, such as [M – H]^− ions with m/z 1120 and 1411, were assigned as mono- and disialylated 6-sulfo core
O-glycans, respectively, based on the sequence obtained after desialylation (Fig. 5). On synovial lubricin isolated from RA patients, the sulfated O-glycans accounted for about 14.6% of core 2 type and 2.6% of the total O-glycans based on mass spectrometric intensities (Fig. 6B).

A low intense parent ion of a disialylated, fucosylated O-glycan ([M – 2H]²⁺ ion of m/z 738, NeuAc₂HexHexNAC₂-deHex₂) indicated a potential sLe⁺ epitope on synovial lubricin (Fig. 5D). The MS/MS spectrum of the parent ion of m/z 738 showed that it was a core 2 type O-glycan. This structure was

FIGURE 5. Sialylated and sulfated core 2 O-glycans on SF lubricin determined by LC-MS in the negative ion mode. A, MS/MS spectrum of a desialylated core 2 oligosaccharide with a [M – H]⁻ ion of m/z 749. The inset shows the expanded region of linkage-specific 0,2A ions for type 2 (Galβ1–4GlcNAc) linkage. B, MS/MS spectrum of a desialylated sulfated core 2 oligosaccharide with an [M – H]⁻ ion of m/z 829. The inset shows the MS² spectrum of the fragment ion at m/z 282, which is consistent with GlcNAc6S; C, MS/MS spectrum of sialylated and sulfated core 2 O-glycan with an [M – 2H]²⁺ ion of m/z 706. D, MS/MS spectrum of an sLe⁺-containing core 2 O-glycan with an [M – 2H]²⁺ ion of m/z 738. Proposed structures and fragments are featured as insets in each spectrum. The nomenclature of fragments is based on the rules introduced by Domon and Costello (68).

2 O-glycans, respectively, based on the sequence obtained after desialylation (Fig. 5C). On synovial lubricin isolated from RA patients, the sulfated O-glycans accounted for about 14.6% of core 2 type and 2.6% of the total O-glycans based on mass spectrometric intensities (Fig. 6B).
only detectable in some samples (n = 7 of 10). Due to the low abundance of this glycan (0.7% of core 2 type and less than 0.1% of total O-glycans), limited structural information was obtained by MS/MS. When using CSLEX-1 mAb (mouse anti-sLeα monoclonal antibody) probed with synovial lubricin, positive staining was observed (Fig. 6A). It demonstrated the presence of the sLeα epitope and low abundance of this epitope. Further modification of this structure, such as sulfation, which leads to 6-sulfo sLeα, was not detectable by LC-MS. The central mucin-like domain of human synovial lubricin consists of 59 imperfectly tandem repeat units (EPATTPK) with dense O-linked oligosaccharides attached to serine or threonine residues. Based on mass spectrometric intensities, even with the most optimistic estimation of the glycosylation with two glycosylation sites per tandem repeat, the amount of sLeα will be less than one epitope per lubricin molecule.

There were also two potential N-glycosylation sites (Asn206 and Asn1159) on lubricin. The second N-glycosylation site has been identified recently from human blood plasma lubricin (52). In this study, non-glycosylated peptide (N1159GTLVAFR, [M + 2H]2+ ion of m/z 439.7403) was detected in synovial lubricin (Table 1), indicating that the second N-glycosylation site on synovial lubricin was not fully occupied, if occupied at all. The peptide containing the first N-glycosylation site was not detected. The sequence of lubricin and the proteomic data indicated that N-glycosylation was low and cannot provide the high avidity required for L-selectin binding (53, 54).

In addition, we failed to identify chondroitin sulfate (CS) on lubricin using the CS-specific mAb CS-56, which readily detected CS in bovine aggrecan (Fig. 6A, mAb CS56), which was confirmed by LC-MS after chondroitinase ABC treatment using bovine aggrecan as a control (data not shown). However, we found that the apparent polydispersity of lubricin was lower after chondroitinase ABC treatment of synovial fluid (Fig. 6A). A similar result was obtained when synovial lubricin was treated with hyaluronidase (Fig. 6A, HA) indicating that residual hyaluronidase activity of chondroitinase ABC and synovial hyaluronic acid influence the migration of lubricin in SDS-AgPAGE.

Taken together, all of these data indicate that sLeα epitopes and CS side chains are not the prime ligand for L-selectin binding of lubricin but rather the cluster of sialylated and sulfated oligosaccharides on the tandem repeat of lubricin, which all together provide a patch for L-selectin binding.

**Proteomic Analysis of Human Synovial Lubricin**—To identify SF lubricin, the bands corresponding to lubricin were excised, trypsinized, and subjected to proteomic analysis. The LC-MS identified 74.9% peptides of the non-mucin domain (residues 1–199 and 1141–1404) (Table 1). We also observed the non-glycosylated mucin repeat unit tryptic peptide, EPAPTPK (m/z 417.7132±) from the mucin domain (residues 200–1140), indicating that not all potential O-glycosylation sites were occupied. This shows that the amount of glycan epitope sLeα is even less on lubricin compared with all threonines are occupied in the mucin domain.

There are five splice variants that have been reported on lubricin (4, 7). Isoform A consists of exons 1–12 (Swiss-Prot number Q92954-1); isoform B (Q92954-2) lacks exon 2; isoform C (Q92954-3) lacks exons 4 and 5; isoform D (Q92954-4) lacks exons 2, 4, and 5; and isoform F (Q92954-6), also known as...
hemangiopoietin, lacks exon 5. Our proteomic results identified peptides derived from all exons except exon 1 (Table 1). These data suggest that if only a single isoform is present in synovial fluid, it is isoform A, but it is more likely that we are detecting a mixture of several isoforms.

**DISCUSSION**

Because the expression level of lubricin in SF has been associated with disease stage of arthritis, lubricin may serve as a potential arthritic biomarker like glycosaminoglycans and cartilage proteins (e.g. aggrecan, heparin sulfate, and cartilage oligomeric matrix protein) (55, 56). Lubricin is a mucin-like glycoprotein. The diverse O-glycan structures and multiple protein domains of lubricin endow properties not only for boundary lubrication but also for other biological functions, including protection of chondrocytes.

In this study, lubricin was found to be able to bind to L-selectin (Figs. 1–3), suggesting that lubricin is a novel L-selectin ligand. There are three groups of L-selectin ligands: the orthodox ligands with 6-sulfo sLex structure on sialomucins and glycoproteins (i.e. GlyCAM-1 (glycosylation cell adhesion molecule-1), CD34, podocalyxin, and MADCAM-1 (mucosal vascular addressin)); ligands with clusters of sLex and Tyr-SO\(_3\) like PSGL-1 (P-selectin-glycoprotein ligand-1) and endoglycan; and proteoglycans with predominantly heparan or chondroitin sulfate modifications (57–59). However, lubricin is different from those identified L-selectin ligands. We did not find extended core 1 O-glycan structures. Only a low amount of sLex could be found on core 2 O-glycan (Figs. 5D and 6A). However, the 6-sulfo sLex epitope was absent on lubricin isolated from 10 RA patients. This suggests that L-selectin may actually recognize a conformational "clustered saccharide patch" rather than a linear defined epitope on lubricin. Thus, the interaction between L-selectin and lubricin is suggested to be weaker than high affinity L-selectin ligands. Inhibition ELISA (Fig. 1C) confirmed that when using 6-sulfo Le\(\alpha\), the binding of lubricin to L-selectin was inhibited significantly. A similar clustered saccharide patch could be found in the closely packed oligosaccharides of mucins or in densely modified heparan/chondroitin sulfate glycosaminoglycans (60, 61). However, our result showed that lubricin was devoid of heparan/chondroitin sulfate (Fig. 6A). Although the apparent polydispersity was reduced upon chondroitinase ABC treatment, this was probably due to the trace hyaluronidase activity of chondroitinase ABC. When samples were treated with hyaluronidase, a similar result as with chondroitinase ABC treatment was obtained, indicating the presence of interaction between lubricin and undigested hyaluronic acid in the sample. This result is consistent with a recent study in which a protein-rich lubricin fraction was devoid of chondroitin sulfate (17). Therefore, the sialylated and sulfated glycans may play a key role in the interaction with L-selectin.

In this study, the sulfated O-linked oligosaccharides present on lubricin from RA patients account for 2.6% of total O-glycans and 14.1% of core 2 O-glycans (Fig. 6B). All sulfate groups on lubricin are linked to the 6-position of GlcNAc on core 2 O-glycan structures as determined by MS\(^3\) spectrum (Fig. 2B). There are two 6-O-sulfotransferases, GlcNAc6ST-1 and -2, responsible for transferring the sulfate group to the GlcNAc residue and also essential for L-selectin ligand biosynthesis. GlcNAc6ST-2 (also known as LSST and HEC-GlcNAc6ST) is restrictedly expressed in high endothelial cells. A study has shown that the expression of GlcNAc6ST-2 was detected in endothelia in RA tissue but not in OA (62). However, in our previous study, sulfated core 2 type
O-glycans were also found in OA patients (34). Thus, GlcNAc6ST-1 is more likely to be responsible for sulfation of synovial lubricin.

To our knowledge, this is the first report of the presence of lubricin on the surface of both peripheral and synovial PMN, and in part, this interaction was executed by association with L-selectin on the cell surface (Figs. 2–4). Upon stimulation with TNF-α, most lubricin was shed off together with L-selectin. In the circulation, the presence of L-selectin-tethered lubricin may be expected to compete with membrane-bound higher affinity L-selectin ligands and influence the rolling of leukocytes on the surface of endothelial cells. In joints, the presence of negatively charged lubricin on cartilage protects cartilage surfaces and underlying superficial zone chondrocytes by inhibiting protein deposit and cell overgrowth (20). Most PMN coated with lubricin may be electrostatically repelled from cartilage surfaces in a similar manner. Defects of the replenishing layer of lubricin on the synovial lining (e.g. down-regulation or increasing protease activity in SF) may result in loss of protection. In this scenario, cells in synovial fluid (e.g. PMN) may adhere to cartilage, leading to destruction of cartilage. It has been reported that low expression levels of lubricin were associated with a strong synovial stromal activation (22), characterized by the infiltration of T cells and macrophages, and was associated with a higher destructive potential and a worse prognosis (63). Prg4 knock-out mice exhibited a degenerative phenotype, including synovial hyperplasia and abnormal cartilage surface (64).

There are two things of particular importance in this study: first, the presence of lubricin in plasma and, second, that not only L-selectin but also another receptor(s) on PMN is able to bind to lubricin. Although the presence in plasma has been reported (7, 14), the origin and properties (e.g. splicing variant, glycosylation) of this lubricin have not been fully characterized. In this study, serum lubricin was demonstrated to be of a size similar to that of SF lubricin, and the protein levels in both compartments were similar. It is not clear whether serum lubricin has the same origin as synovial lubricin, but it has been indicated that intra-articular injection of recombinant lubricin constructs will deposit on an area of post-traumatic arthritis damage in a rat model (65). The origin and biological functions of serum lubricin are worthy of further investigation.

That lubricin binds PMN also in a non-L-selectin-dependent manner suggests that an additional PMN receptor(s) is also involved. Siglec-9 (sialic acid-binding immunoglobulin-like lectin 9) could be one of these receptors, which recognizes both α2,3- and α2,6-linked NeuAc (66) and is up-regulated on neutrophils in RA patients (67).

In summary, we demonstrated the presence of sLeα epitopes on lubricin. These glycoepitopes enable lubricin to bind to L-selectin. We also detected the presence of lubricin on both peripheral and synovial PMN, indicating a role in inflammation by influencing the interaction between PMN and other cells.

Acknowledgment—We thank C. R. Flannery (Wyeth Research, Cambridge, MA) for providing lubricin-specific antibody (mAb 13).

REFERENCES

L-selectin Ligand Activity of Lubricin


